Esophageal adenocarcinoma stage III: survival based on pathological response to neoadjuvant treatment

K Schwameis, J Zehetner, JA Hagen, DS Oh… - Surgical Oncology, 2017 - Elsevier
Background Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced
esophageal adenocarcinomas (EAC). Pathological response is thought to be a major …
被引用次数：7 相关文章

Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.

K Schwameis, J Zehetner, JA Hagen, DS Oh… - Surgical …, 2017 - europepmc.org
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced esophageal
adenocarcinomas (EAC). Pathological response is thought to be a major prognostic factor …

Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment

K Schwameis, J Zehetner, JA Hagen… - Surgical …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced
esophageal adenocarcinomas (EAC). Pathological response is thought to be a major …